Literature DB >> 28385699

Treating sickle cell disease by targeting HbS polymerization.

William A Eaton1, H Franklin Bunn2.   

Abstract

Although the root cause of sickle cell disease is the polymerization of hemoglobin S (HbS) to form fibers that make red cells less flexible, most drugs currently being assessed in clinical trials are targeting the downstream sequelae of this primary event. Less attention has been devoted to investigation of the multiple ways in which fiber formation can be inhibited. In this article, we describe the molecular rationale for 5 distinct approaches to inhibiting polymerization and also discuss progress with the few antipolymerization drugs currently in clinical trials.

Mesh:

Substances:

Year:  2017        PMID: 28385699      PMCID: PMC5437829          DOI: 10.1182/blood-2017-02-765891

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  102 in total

1.  Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions.

Authors:  Efemwonkiekie W Iyamu; Ernest A Turner; Toshio Asakura
Journal:  Br J Haematol       Date:  2003-09       Impact factor: 6.998

2.  Analysis of non-ideal behavior in concentrated hemoglobin solutions.

Authors:  P D Ross; A P Minton
Journal:  J Mol Biol       Date:  1977-05-25       Impact factor: 5.469

3.  Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins.

Authors:  H R Sunshine; J Hofrichter; W A Eaton
Journal:  J Mol Biol       Date:  1979-10-09       Impact factor: 5.469

4.  2,3-diphosphoglycerate phosphatase from human erythrocytes. General properties and activation by anions.

Authors:  Z B Rose; J Liebowitz
Journal:  J Biol Chem       Date:  1970-06       Impact factor: 5.157

5.  Solubilization of hemoglobin S by other hemoglobins.

Authors:  R E Benesch; R Edalji; R Benesch; S Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

Review 6.  Hemoglobin S gelation and sickle cell disease.

Authors:  W A Eaton; J Hofrichter
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

7.  Vanillin, a potential agent for the treatment of sickle cell anemia.

Authors:  D J Abraham; A S Mehanna; F C Wireko; J Whitney; R P Thomas; E P Orringer
Journal:  Blood       Date:  1991-03-15       Impact factor: 22.113

Review 8.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

9.  Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo.

Authors:  A Mozzarelli; J Hofrichter; W A Eaton
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

10.  A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an alpha2 globin gene variant (Hb Conakry).

Authors:  M Cohen-Solal; C Préhu; H Wajcman; C Poyart; J Bardakdjian-Michau; J Kister; D Promé; C Valentin; D Bachir; F Galactéros
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

View more
  67 in total

1.  High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension.

Authors:  Giuseppe Di Caprio; Ethan Schonbrun; Bronner P Gonçalves; Jose M Valdez; David K Wood; John M Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-25       Impact factor: 11.205

Review 2.  Gene therapy for sickle cell disease: An update.

Authors:  Selami Demirci; Naoya Uchida; John F Tisdale
Journal:  Cytotherapy       Date:  2018-05-30       Impact factor: 5.414

Review 3.  Targeting novel mechanisms of pain in sickle cell disease.

Authors:  Huy Tran; Mihir Gupta; Kalpna Gupta
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

4.  Treating sickle cell anemia.

Authors:  John F Tisdale; Swee Lay Thein; William A Eaton
Journal:  Science       Date:  2020-03-13       Impact factor: 47.728

5.  Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice.

Authors:  Nadine Keleku-Lukwete; Mikiko Suzuki; Harit Panda; Akihito Otsuki; Fumiki Katsuoka; Ritsumi Saito; Daisuke Saigusa; Akira Uruno; Masayuki Yamamoto
Journal:  Blood Adv       Date:  2019-04-23

Review 6.  Fetal hemoglobin in sickle cell anemia.

Authors:  Martin H Steinberg
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 7.  Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence.

Authors:  Varun Sagi; Donovan A Argueta; Stacy Kiven; Kalpna Gupta
Journal:  Complement Ther Med       Date:  2020-05-11       Impact factor: 2.446

8.  Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease.

Authors:  Panae Noomuna; Mary Risinger; Sitong Zhou; Katie Seu; Yuncheng Man; Ran An; Daniel A Sheik; Jiandi Wan; Jane A Little; Umut A Gurkan; Francesco M Turrini; Theodosia Kalfa; Philip S Low
Journal:  Br J Haematol       Date:  2020-04-28       Impact factor: 6.998

9.  Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies.

Authors:  Selami Demirci; Alexis Leonard; John F Tisdale
Journal:  Hum Mol Genet       Date:  2020-09-30       Impact factor: 6.150

Review 10.  Targeting novel mechanisms of pain in sickle cell disease.

Authors:  Huy Tran; Mihir Gupta; Kalpna Gupta
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.